It is also linked to the recently published WAO guidelines ( 3 ) which are partially conflicting with the previous conclusion because it suggests that ‘ using probiotics in women who breastfeed infants at high risk of developing allergy , because considering all critical outcomes , there is a net benefit result ing primarily from prevention of eczema ( conditional recommendation , very low quality evidence ) ’ .
A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years
Using a double blind r and omized placebo‐controlled trial ( Australian New Zeal and Clinical Trials Registry : ACTRN12607000518460 ) , we have shown that in a high risk birth cohort , maternal supplementation from 35 weeks gestation until 6 months if breastfeeding and infant supplementation until 2 years with Lactobacillus rhamnosus HN001 ( HN001 ) ( 6 × 109 cfu/day ) halved the cumulative prevalence of eczema by age 2 years . Bifidobacterium animalis subsp lactis HN019 ( HN019 ) ( 9 × 109 cfu/day ) had no effect
It is also linked to the recently published WAO guidelines ( 3 ) which are partially conflicting with the previous conclusion because it suggests that ‘ using probiotics in women who breastfeed infants at high risk of developing allergy , because considering all critical outcomes , there is a net benefit result ing primarily from prevention of eczema ( conditional recommendation , very low quality evidence ) ’ .